A carregar...
Repurposed agents in the Alzheimer’s disease drug development pipeline
BACKGROUND: Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug repurpos...
Na minha lista:
| Publicado no: | Alzheimers Res Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433208/ https://ncbi.nlm.nih.gov/pubmed/32807237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00662-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|